Influenza treatment with neuraminidase inhibitors
- 1 September 2005
- journal article
- Published by Springer Science and Business Media LLC in The European Journal of Health Economics
- Vol. 6 (3), 244-252
- https://doi.org/10.1007/s10198-005-0297-y
Abstract
Influenza, Treatment, Antivirals, Cost-effectiveness, Decision modeling,Keywords
This publication has 19 references indexed in Scilit:
- Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and HospitalizationsArchives of Internal Medicine, 2003
- Economic Costs of Influenza-Related Work AbsenteeismValue in Health, 2003
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working AdultsPharmacoEconomics, 2003
- Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlledBMJ, 2001
- Community-Acquired PneumoniaMedicine, 2001
- The Impact of Influenza Epidemics on HospitalizationsThe Journal of Infectious Diseases, 2000
- Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute InfluenzaJAMA, 2000
- Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European StudyJournal of Infection, 2000
- The Economic Impact of Pandemic Influenza in the United States: Priorities for InterventionEmerging Infectious Diseases, 1999